DNTH
Dianthus Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +6.1% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 95 | +11 | 36.60M | $3.56B | +15 | −4 |
| Q1 2026 | 87 | +18 | 31.37M | $2.59B | +21 | −3 |
| Q4 2025 | 69 | +2 | 26.03M | $1.07B | +3 | −1 |
| Q3 2025 | 16 | +2 | 17.27M | $679.58M | +2 | — |
| Q2 2025 | 11 | +1 | 11.18M | $208.23M | +1 | — |
| Q1 2025 | 7 | -2 | 3.50M | $63.53M | — | −2 |
| Q4 2024 | 9 | -1 | 2.27M | $49.52M | +1 | −2 |
| Q3 2024 | 9 | +3 | 1.20M | $32.83M | +4 | −1 |
| Q2 2024 | 6 | — | 1.13M | $29.26M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 485.12K | -2.8% | $13.29M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Point72 Asset Management ✦ | 437.70K | +151.3% | $11.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 59.30K | New | $1.62M | 0.0% | New | 1 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 55.42K | -37.5% | $1.52M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Marshall Wace ✦ | 53.85K | -50.2% | $1.47M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 53.78K | New | $1.47M | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 34.75K | New | $951,565 | 0.0% | New | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 11.19K | +6.6% | $306,355 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 7.82K | New | $215,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $1.62M | 0.0% |
| Wellington Management | $1.47M | 0.0% |
| Millennium Management | $951,565 | 0.0% |
| T. Rowe Price | $215,000 | 0.0% |
Exited
| Adage Capital Partners | $6.47M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 62.10M shares, $4.94B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.93K sh · $796,209
Officer · 700 sh · $73,073
Officer · 1.10K sh · $113,520
Officer · 3.50K sh · $358,467
Officer · 6.77K sh · $686,376
Officer · 13.31K sh · $1.42M
Officer · 7.21K sh · $766,594
Officer · 2.60K sh · $273,494
Director · 2.78K sh · $326,554
Director · 1.45K sh · $155,991
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology